Received: 30 August 2022
Accepted: 9 December 2022
First Online: 19 December 2022
: The patient was diagnosed with bladder cancer, and after accepting standard first-line chemotherapy based on platinum, the cancer metastasized. According to China’s National Medical Products Administration (NMPA) in 2020, tislelizumab can be used for the treatment of locally advanced or metastatic urothelial carcinoma in patients who have failed to respond to first-line chemotherapy. As a result, tislelizumab administration is reasonable and appropriate in this patient’s situation, without exceeding the drug’s indication, and does not require prior approval from the ethics committee. In addition, we have obtained the patient’s consent before using tislelizumab. Meanwhile, we have reorganized the case presentation and now have a better understanding of the patient’s condition.Written informed consent was obtained from individual participants.
: All data published here are under the consent for publication. Written informed consent was obtained from all individual participants included in the study.
: The authors declare that they have no competing interests.